Extended Data Fig. 3 |. Disruption of barrier integrity drives PMP.

a, FITC-dextran concentration in blood plasma correlates with numbers of LSK cells (left, n = 12 mice), frequency of CD11b⁺Gr1⁺ myeloid cells in the spleen (middle left, n = 10 mice), peripheral blood (middle right, n = 15 mice) and frequency of lymphocytes (right, n = 15 mice). Pearson correlation test. b, Schematic of DSS treatment of symptom-free Tet2^f/fVav^cre mice that are over 20 weeks old, and littermate controls. c, Numbers of CD11b⁺ monocytes (left), lymphocytes (middle) and leukocytes (WBC) (right) before, during and after DSS treatment (n = 5 (blue) or 8 (orange) mice). Mean ± s.e.m. d, Percentage of CD11b⁺Gr1⁺ myeloid cells (left) and numbers of GMP (right) at end point analysis (n = 5 (Tet2^f/fcre⁻, without DSS), 4 (Tet2^f/fVav^cre, without DSS), 6 (Tet2^f/fcre⁻, with DSS) or 8 (Tet2^f/fVav^cre, with DSS) mice). Centre is median, Kruskal–Wallis, Dunn’s post hoc test. *P < 0.05, **P < 0.01. Data are representative of at least two independent experiments.